Pharmaceuticals

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A new collaboration between Emporia Research and Definitive Healthcare promises unprecedented accuracy in recruiting healthcare decision-makers for vital research.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

Jetstream Venture Fund's deals with Surf Therapeutics and Hill Research signal a new era of accessible venture capital backing transformative technologies.

The tech leader will showcase an integrated platform turning supply chain complexity and regulatory hurdles like the Digital Product Passport into a competitive edge.

A new company is selling franchises to doctors and pharmacists, promising to cut out insurers and restore local care. But can this bold model survive the system?

Ditching the static model, CleanSpace is building a full-scale, operational pharmaceutical factory on the tradeshow floor, a move set to transform B2B marketing.

Powered Research will unveil an AI that speeds drug testing for retinal diseases and key findings on animal models, aiming to transform preclinical studies.

In a significant move, 35 workers at a key biopharmaceutical firm supporting the CDC and FDA have unionized, highlighting new frontiers for organized labor.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.

Behavior Labs launches a new platform to close the life sciences' 'ground truth gap,' replacing slow quarterly reviews with continuous, daily intelligence.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

With Nuvaxovid set for a 2026 rollout, Sanofi aims to address vaccine hesitancy and expand choices as Canada continues to battle the virus.